OncoPharm

John Bossaer

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

  1. Axi-Cel and 5-FU Label Changes

    -2 ДН.

    Axi-Cel and 5-FU Label Changes

    We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

    13 мин.

  2. 5 ФЕВР.

    Core Communication Skills in Chemotherapy Education

    A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

    15 мин.
  3. PATINA

    29 ЯНВ.

    PATINA

    Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

    16 мин.
  4. Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    22 ЯНВ.

    Sacituzumab govitecan + pembrolizumab and ASCO GI '26

    We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

    18 мин.
  5. Oncology Drug Use Evolution

    15 ЯНВ.

    Oncology Drug Use Evolution

    This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time. Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

    11 мин.
  6. 2025 New Drug Review

    8 ЯНВ.

    2025 New Drug Review

    A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

    15 мин.
  7. Bladder Cancer Updates & SC Amivantamab

    18.12.2025

    Bladder Cancer Updates & SC Amivantamab

    Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion reactions - but some chances for dosing errors based on weights and available dosage forms.

    13 мин.
  8. ASH 2025

    11.12.2025

    ASH 2025

    ASH 2025 Highlights: MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Denosumab safety & dosing in Multiply Myeloma and renal dysfunction Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?

    29 мин.
См. все (414)

Об этом подкасте

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Информация

  • Автор
    John Bossaer
  • Годы выхода
    2017 - 2026
  • Выпуски
    414
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © All rights reserved
  • Сайт подкаста
    OncoPharm

Вам может также понравиться